As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular ...
Three days ago, on August 4, Amgen ( AMGN) released another strong earnings report. Its revenue was $10.1 billion, up 16.6% ...
The recommendation is based on data from the Phase III VESALIUS-CV trial, which involved more than 12,000 patients.
Amgen (NasdaqGS:AMGN) received a positive opinion from the European Medicines Agency’s CHMP for an expanded Repatha ...
Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
MarketBeat on MSN
Amgen Q2 earnings call highlights
Key Points Interested in Amgen Inc.? Here are five stocks we like better. Amgen reported strong second-quarter results, with ...
Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
Amgen Inc. ( AMGN) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDT My name is Julianne, and I will be your conference facilitator today for the Amgen Q2 Earnings Conference Call. I would now like to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results